Vivacta Biotechnology

Vivacta Biotechnology was established on June 25, 2025, spun off from the in vivo CAR-T platform of Beijing Gracell Biopharmaceuticals Co., Ltd. (“Gracell Biopharmaceuticals”). Leveraging an in vivo CAR-T therapy developed based on a targeted lipid nanoparticle (LNP) delivery system, Vivacta Biotechnology is dedicated to providing innovative therapeutic solutions for hematologic malignancies and autoimmune diseases. This approach enables direct CAR expression within patients’ T cells, eliminating the need for cell separation, expansion, and lymphodepletion preconditioning associated with traditional autologous CAR-T therapies. By fundamentally addressing the three core pain points of autologous CAR-T therapy—high cost, long turnaround time, and significant toxicity—it promises to significantly shorten the treatment timeline, facilitate the evolution of cell therapy toward off-the-shelf pharmaceutical products, and substantially improve patient accessibility. Furthermore, Vivacta’s targeted LNP delivery system demonstrates outstanding performance in precision, safety, and manufacturing compatibility. Its unique technical pathway enhances T-cell targeting efficiency, effectively reduces off-target risks, and is compatible with large-scale production using mRNA/LNP manufacturing lines. The company’s proprietary targeting technology achieves highly efficient and sustained CAR expression in T cells, demonstrating excellent B-cell depletion efficacy across multiple preclinical models and a favorable safety profile upon repeated dosing.